Joseph A Nicolazzo

List of Publications by Year
in descending order

81 papers	3,233 citations	201674 27 h-index	155660 55 g-index
82 all docs	82 docs citations	82 times ranked	4709 citing authors

#	Article	IF	Citations
1	Blockade of Microglial Kv1.3 Potassium Channels by the Peptide HsTX1[R14A] Attenuates Lipopolysaccharide-mediated Neuroinflammation. Journal of Pharmaceutical Sciences, 2022, 111, 638-647.	3.3	9
2	Altered bloodâ€"brain barrier and bloodâ€"spinal cord barrier dynamics in amyotrophic lateral sclerosis: Impact on medication efficacy and safety. British Journal of Pharmacology, 2022, 179, 2577-2588.	5.4	18
3	Copper bis(thiosemicarbazone) complexes modulate Pâ€glycoprotein expression and function in human brain microvascular endothelial cells. Journal of Neurochemistry, 2022, , .	3.9	9
4	Altered peripheral factors affecting the absorption, distribution, metabolism, and excretion of oral medicines in Alzheimerâ€™s disease. Advanced Drug Delivery Reviews, 2022, 185, 114282.	13.7	4
5	A Combination of Clioquinol, Zinc and Copper Increases the Abundance and Function of Breast Cancer Resistance Protein in Human Brain Microvascular Endothelial Cells. Journal of Pharmaceutical Sciences, 2021, 110, 338-346.	3.3	4
6	Prolonged Plasma Exposure of the Kv1.3-Inhibitory Peptide HsTX1[R14A] by Subcutaneous Administration of a Poly(Lactic-co-Glycolic Acid) (PLGA) Microsphere Formulation. Journal of Pharmaceutical Sciences, 2021, 110, 1182-1188.	3.3	6
7	Potential Mechanism of Cellular Uptake of the Excitotoxin Quinolinic Acid in Primary Human Neurons. Molecular Neurobiology, 2021, 58, 34-54.	4.0	4
8	Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides. International Journal of Pharmaceutics, 2021, 599, 120398.	5.2	10
9	Lipopolysaccharide influences the plasma and brain pharmacokinetics of subcutaneously-administered HsTX1[R14A], a KV1.3-blocking peptide. Toxicon, 2021, 195, 29-36.	1.6	5
10	Development of a Vertically Integrated Pharmacy Degree. Pharmacy (Basel, Switzerland), 2021, 9, 156.	1.6	7
11	Increasing Intracellular Levels of Iron with Ferric Ammonium Citrate Leads to Reduced P-glycoprotein Expression in Human Immortalised Brain Microvascular Endothelial Cells. Pharmaceutical Research, 2021, 38, 97-111.	3.5	4
12	Nitrile-Functionalized Poly(2-oxazoline)s as a Versatile Platform for the Development of Polymer Therapeutics. Biomacromolecules, 2021, 22, 4618-4632.	5.4	10
13	Antibody Drug Conjugates in Glioblastoma â€" Is There a Future for Them?. Frontiers in Oncology, 2021, 11, 718590.	2.8	14
14	The hyperpolarizationâ€activated cyclic nucleotideâ€gated 4 channel as a potential antiâ€seizure drug target. British Journal of Pharmacology, 2020, 177, 3712-3729.	5.4	14
15	Intestinal Permeability and Oral Absorption of Selected Drugs Are Reduced in a Mouse Model of Familial Alzheimerâ€™s Disease. Molecular Pharmaceutics, 2020, 17, 1527-1537.	4.6	10
16	Pioglitazone Increases Bloodâ€"Brain Barrier Expression of Fatty Acid-Binding Protein 5 and Docosahexaenoic Acid Trafficking into the Brain. Molecular Pharmaceutics, 2020, 17, 873-884.	4.6	13
17	Development and validation of a LC-MS/MS assay for quantifying the uptake of docosahexaenoic acid-d5 into mouse microglia. Journal of Pharmaceutical and Biomedical Analysis, 2020, 191, 113575.	2.8	2
18	Impact of reduced Pâ€glycoprotein function on digoxin concentrations in patients with dementia. British Journal of Clinical Pharmacology, 2019, 85, 2351-2359.	2.4	3

#	Article	IF	Citations
19	The Effects of Clioquinol on P-glycoprotein Expression and Biometal Distribution in the Mouse Brain Microvasculature. Journal of Pharmaceutical Sciences, 2019, 108, 2247-2255.	3.3	5
20	Increased Expression of Renal Drug Transporters in a Mouse Model of Familial Alzheimer's Disease. Journal of Pharmaceutical Sciences, 2019, 108, 2484-2489.	3.3	13
21	The flavonoid, 2â€²-methoxy-6-methylflavone, affords neuroprotection following focal cerebral ischaemia. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1266-1282.	4.3	18
22	Ionophore and Biometal Modulation of P-glycoprotein Expression and Function in Human Brain Microvascular Endothelial Cells. Pharmaceutical Research, 2018, 35, 83.	3.5	16
23	Effect of Permeation Enhancers on the Buccal Permeability of Nicotine: Ex vivo Transport Studies Complemented by MALDI MS Imaging. Pharmaceutical Research, 2018, 35, 70.	3.5	16
24	Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics. Advanced Drug Delivery Reviews, 2018, 135, 62-74.	13.7	78
25	Dietary docosahexaenoic acid supplementation enhances expression of fatty acidâ€binding protein 5 at the bloodâ€"brain barrier and brain docosahexaenoic acid levels. Journal of Neurochemistry, 2018, 146, 186-197.	3.9	11
26	Fatty Acidâ€"Binding Protein 5 Mediates the Uptake of Fatty Acids, but not Drugs, Into Human Brain Endothelial Cells. Journal of Pharmaceutical Sciences, 2018, 107, 1185-1193.	3.3	18
27	Cognitive benefits of lithium chloride in APP/PS1 mice are associated with enhanced brain clearance of Î²-amyloid. Brain, Behavior, and Immunity, 2018, 70, 36-47.	4.1	34
28	Reduced bloodâ€brain barrier expression of fatty acidâ€binding protein 5 is associated with increased vulnerability of APP/PS1 mice to cognitive deficits from low omegaâ€3 fatty acid diets. Journal of Neurochemistry, 2018, 144, 81-92.	3.9	18
29	Commentary on the 2018 Named Series on blood-brain interfaces: Roles of neuroimmunomodulation in health and disease. Brain, Behavior, and Immunity, 2018, 74, 3-6.	4.1	1
30	Altered Expression of Small Intestinal Drug Transporters and Hepatic Metabolic Enzymes in a Mouse Model of Familial Alzheimerâ€™s Disease. Molecular Pharmaceutics, 2018, 15, 4073-4083.	4.6	23
31	Assessing the Impact of Lithium Chloride on the Expression of P-Glycoprotein at the Blood-Brain Barrier. Journal of Pharmaceutical Sciences, 2017, 106, 2625-2631.	3.3	10
32	Development and Validation of an In-Cell Western for Quantifying P-Glycoprotein Expression in Human Brain Microvascular Endothelial (hCMEC/D3) Cells. Journal of Pharmaceutical Sciences, 2017, 106, 2614-2624.	3.3	12
33	Lysine to arginine mutagenesis of chlorotoxin enhances its cellular uptake. Biopolymers, 2017, 108, e23025.	2.4	12
34	Neurovascular Alterations in Alzheimerâ€™s Disease: Transporter Expression Profiles and CNS Drug Access. AAPS Journal, 2017, 19, 940-956.	4.4	16
35	A Tribute to Ronald T. Borchardtâ€"Teacher, Mentor, Scientist, Colleague, Leader, Friend, and Family Man. Journal of Pharmaceutical Sciences, 2016, 105, 370-385.	3.3	4
36	Fatty Acid-Binding Protein 5 at the Bloodâ€"Brain Barrier Regulates Endogenous Brain Docosahexaenoic Acid Levels and Cognitive Function. Journal of Neuroscience, 2016, 36, 11755-11767.	3.6	61

#	Article	IF	Citations
37	Enabling Noninvasive Systemic Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] via the Buccal Mucosa. Journal of Pharmaceutical Sciences, 2016, 105, 2173-2179.	3.3	17
38	Validation and Characterization of a Novel Peptide That Binds Monomeric and Aggregated Î²-Amyloid and Inhibits the Formation of Neurotoxic Oligomers. Journal of Biological Chemistry, 2016, 291, 547-559.	3.4	15
39	Quantitation of Polymyxinâ€“Lipopolysaccharide Interactions Using an Image-Based Fluorescent Probe. Journal of Pharmaceutical Sciences, 2016, 105, 1006-1010.	3.3	15
40	Pulmonary Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] for the Treatment of Autoimmune Diseases. Journal of Pharmaceutical Sciences, 2016, 105, 650-656.	3.3	27
41	Enhancing the Buccal Mucosal Delivery of Peptide and Protein Therapeutics. Pharmaceutical Research, 2015, 32, 1-21.	3.5	94
42	Drug Access to the Central Nervous System in Alzheimerâ€™s Disease: Preclinical and Clinical Insights. Pharmaceutical Research, 2015, 32, 819-839.	3.5	34
43	Fatty Acid-Binding Protein 5 Facilitates the Bloodâ€“Brain Barrier Transport of Docosahexaenoic Acid. Molecular Pharmaceutics, 2015, 12, 4375-4385.	4.6	88
44	Fatty Acid Binding Proteins Expressed at the Human Bloodâ€“Brain Barrier Bind Drugs in an Isoform-Specific Manner. Pharmaceutical Research, 2015, 32, 3432-3446.	3.5	9
45	Buccal mucosal delivery of a potent peptide leads to therapeutically-relevant plasma concentrations for the treatment of autoimmune diseases. Journal of Controlled Release, 2015, 199, 37-44.	9.9	26
46	The Impact of Docosahexaenoic Acid on Alzheimerâ€™s Disease: Is There a Role of the Blood-Brain Barrier?. Current Clinical Pharmacology, 2015, 10, 222-241.	0.6	37
47	Exploiting the Buccal Mucosa as an Alternative Route for the Delivery of Donepezil Hydrochloride. Journal of Pharmaceutical Sciences, 2014, 103, 1643-1651.	3.3	10
48	Synthesis, Structureâ€“Activity Relationships and Brain Uptake of a Novel Series of Benzopyran Inhibitors of Insulin-Regulated Aminopeptidase. Journal of Medicinal Chemistry, 2014, 57, 1368-1377.	6.4	46
49	The Lymphatic System Plays a Major Role in the Intravenous and Subcutaneous Pharmacokinetics of Trastuzumab in Rats. Molecular Pharmaceutics, 2014, 11, 496-504.	4.6	49
50	The Effect of Formulation Excipients on the Penetration and Lateral Diffusion of Ibuprofen on and within the Stratum Corneum Following Topical Application to Humans. Journal of Pharmaceutical Sciences, 2014, 103, 909-919.	3.3	16
51	AzoneÂ® Decreases the Buccal Mucosal Permeation of Diazepam in a Concentration-Dependent Manner via a Reservoir Effect. Journal of Pharmaceutical Sciences, 2014, 103, 1133-1141.	3.3	11
52	Altered Brain Uptake of Therapeutics in a Triple Transgenic Mouse Model of Alzheimerâ€™s Disease. Pharmaceutical Research, 2013, 30, 2868-2879.	3.5	53
53	Memantine Transport across the Mouse Bloodâ€“Brain Barrier Is Mediated by a Cationic Influx H⁺ Antiporter. Molecular Pharmaceutics, 2013, 10, 4491-4498.	4.6	48
54	Reduced CNS exposure of memantine in a triple transgenic mouse model of Alzheimer's disease assessed using a novel LCâ€“MS technique. Journal of Pharmaceutical and Biomedical Analysis, 2013, 85, 198-206.	2.8	9

#	Article	IF	Citations
55	Expression of Tryptophan 2,3-Dioxygenase and Production of Kynurenine Pathway Metabolites in Triple Transgenic Mice and Human Alzheimer's Disease Brain. PLoS ONE, 2013, 8, e59749.	2.5	116
56	Species-Dependent Blood-Brain Barrier Disruption of Lipopolysaccharide: Amelioration by Colistin<i>In Vitro</i>and<i>In Vivo</i>. Antimicrobial Agents and Chemotherapy, 2013, 57, 4336-4342.	3.2	29
57	Effect of Systemic Infection Induced by Pseudomonas aeruginosa on the Brain Uptake of Colistin in Mice. Antimicrobial Agents and Chemotherapy, 2012, 56, 5240-5246.	3.2	17
58	The Involvement of a Na⁺- and Cl^{â€“}-Dependent Transporter in the Brain Uptake of Amantadine and Rimantadine. Molecular Pharmaceutics, 2012, 9, 883-893.	4.6	18
59	Computational Prediction of CNS Drug Exposure Based on a Novel In Vivo Dataset. Pharmaceutical Research, 2012, 29, 3131-3142.	3.5	21
60	Biodistribution of polymer hydrogel capsules for the delivery of therapeutics. Acta Biomaterialia, 2012, 8, 3251-3260.	8.3	11
61	Decreased bloodâ€“brain barrier expression of P-glycoprotein in Alzheimerâ€™s disease: impact on pathogenesis and brain access of therapeutic agents. Therapeutic Delivery, 2011, 2, 841-844.	2.2	7
62	Chitosan nanoparticles enhance the plasma exposure of (âˆ’)-epigallocatechin gallate in mice through an enhancement in intestinal stability. European Journal of Pharmaceutical Sciences, 2011, 44, 422-426.	4.0	129
63	Assessment of plasma concentrations of (âˆ’)-epigallocatechin gallate in mice following administration of a dose reflecting consumption of a standard green tea beverage. Food Chemistry, 2011, 128, 7-13.	8.2	17
64	Impact of P-Glycoprotein Inhibition and Lipopolysaccharide Administration on Blood-Brain Barrier Transport of Colistin in Mice. Antimicrobial Agents and Chemotherapy, 2011, 55, 502-507.	3.2	37
65	Transport of drugs across the bloodâ€“brain barrier in Alzheimerâ€™s disease. Therapeutic Delivery, 2010, 1, 595-611.	2.2	15
66	Methods to assess drug permeability across the blood-brain barrier. Journal of Pharmacy and Pharmacology, 2010, 58, 281-293.	2.4	91
67	Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (âˆ’)-epigallocatechin gallate. European Journal of Pharmaceutical Sciences, 2010, 41, 219-225.	4.0	243
68	The Buccal Mucosa as an Alternative Route for the Systemic Delivery of Risperidone. Journal of Pharmaceutical Sciences, 2010, 99, 4584-4592.	3.3	21
69	Effective use of reducing agents and nanoparticle encapsulation in stabilizing catechins in alkaline solution. Food Chemistry, 2010, 122, 662-667.	8.2	167
70	Brain uptake of diazepam and phenytoin in a genetic animal model of absence epilepsy. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 647-649.	1.9	9
71	Brain Penetration of Colistin in Mice Assessed by a Novel High-Performance Liquid Chromatographic Technique. Antimicrobial Agents and Chemotherapy, 2009, 53, 4247-4251.	3.2	35
72	A Novel Flow through Diffusion Cell for Assessing Drug Transport across the Buccal Mucosa In Vitro. Journal of Pharmaceutical Sciences, 2009, 98, 4577-4588.	3.3	18

#	Article	IF	Citations
73	Drug Transport Across the Blood-Brain Barrier and the Impact of Breast Cancer Resistance Protein (ABCG2). Current Topics in Medicinal Chemistry, 2009, 9, 130-147.	2.1	48
74	Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aî². Neuron, 2008, 59, 43-55.	8.1	629
75	Synergistic enhancement of testosterone transdermal delivery. Journal of Controlled Release, 2005, 103, 577-585.	9.9	37
76	Buccal penetration enhancersâ€"How do they really work?. Journal of Controlled Release, 2005, 105, 1-15.	9.9	169
77	Enhancing the buccal mucosal uptake and retention of triamcinolone acetonide. Journal of Controlled Release, 2005, 105, 240-248.	9.9	46
78	Enhanced Buccal Mucosal Retention and Reduced Buccal Permeability of Estradiol in the Presence of Padimate O and AzoneÂ®: A Mechanistic Study. Journal of Pharmaceutical Sciences, 2005, 94, 873-882.	3.3	17
79	Assessment of the effects of sodium dodecyl sulfate on the buccal permeability of caffeine and estradiol. Journal of Pharmaceutical Sciences, 2004, 93, 431-440.	3.3	54
80	Modification of buccal drug delivery following pretreatment with skin penetration enhancers. Journal of Pharmaceutical Sciences, 2004, 93, 2054-2063.	3.3	39
81	The Effect of Various In Vitro Conditions on the Permeability Characteristics of the Buccal Mucosa. Journal of Pharmaceutical Sciences, 2003, 92, 2399-2410.	3.3	77